B
Bull
Bull · 25%SWTX
$153.96
Precio del escenario
$46.990
+0.009 (+0.02%)Al cierre
Loading chart…
- High
- 47.010
- Open
- 46.990
- VWAP
- 46.99
- Vol
- 5.01M
- Mkt Cap
- 2.78B
- Low
- 46.980
- Amount
- 235.48M
- EV/EBITDA, TTM
- -26.05
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
Métricas de valoración
The current forward P/E ratio for SpringWorks Therapeutics Inc (SWTX) is -24.05, compared to its 5-year average forward P/E of -11.52.
Alphio AI Price Scenarios for SWTX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
9.008-18NewsfilterEuropean Commission Approves OGSIVEO® (nirogacestat) for Treating Adults with Desmoid Tumors
5.008-18BenzingaRenowned Investor Stanley Druckenmiller Placed Significant Bets on AI and Chipmakers in Q2 — Discover His Insights.
- 9.006-20Newsfilter
SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors
3.006-16NASDAQ.COMValidea Detailed Fundamental Analysis - SWTX
7.006-15GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPOF, PRA, SWTX on Behalf of Shareholders
SWTX FAQ — answered by Alphio AI
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.